Dr. Oded Sagiv, MD

Dr. Sagiv practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Sagiv's NPI, 1619420247, was assigned on August 1, 2016. Dr. Sagiv graduated from Technion-Israel Inst of Technology Faculty of Medicine in 2012. Dr. Sagiv's Texas license number on file is 48356.

Dr. Sagiv's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Sagiv's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Texas Children's Hospital. Dmand AI also links Dr. Sagiv to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sagiv practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Sagiv's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dmand AI has Dr. Sagiv's licenses on file in 2 states: Texas and Florida.

Dmand AI lists vision problems among the conditions Dr. Sagiv treats.

CMS data shows 466 Medicare services from Dr. Sagiv across 13 procedure codes in 2024, for 238 Medicare patients. Medicare paid $31,695 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 238 Medicare patients who saw Dr. Sagiv in 2024. The largest group is 65 to 74, with 112 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sagiv's median patient age at 72, with 50% women.

In 2024, Dr. Sagiv wrote 23 Medicare Part D claims for 16 patients. 78% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $102 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Sagiv for performance year 2024, reported as part of a group. Dr. Sagiv accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sagiv as offering telehealth. CMS counts 30 procedures of melanoma (skin cancer) excision by Dr. Sagiv, more than 80% of the clinicians it reports for that procedure.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 44 papers to Dr. Sagiv, published from 2013 to 2025. 2024 was the busiest year, with 6. The most frequent topics are Graves Ophthalmopathy, Eyelids and Visual Acuity. Dr. Sagiv has published most often in Ophthalmic Plast Reconstr Surg. Dr. Sagiv's most frequent co-authors are Bita Esmaeli, MD, Thomas J. Kandl, MD and Michael T. Tetzlaff, MD, PhD.

Dmand AI links Dr. Sagiv to 1 clinical trial. Conditions studied include Graves Ophthalmopathy and Exophthalmos.

CMS Open Payments shows 2 general payments to Dr. Sagiv from 1 drug or device company from 2017 to 2018. Food and beverage make up the largest share, 100% of the total. Stryker Corporation paid the most, $180.

Dr. Sagiv graduated from Technion-Israel Inst of Technology Faculty of Medicine in 2012.

Dr. Sagiv is in network with 4 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 3. Check the plan with the practice before a visit.